FDA Labeling for Semaglutide (Prescription Status)
Semaglutide products approved by FDA are prescription medicines. [1][2] FDA product labeling uses the term “healthcare provider” for clinical interactions rather than limiting prescribers to a specific specialty. [1][2] In the FDA label text reviewed for WEGOVY, the terms “cardiologist” and “endocrin” did not appear. [3][4] In the FDA label text reviewed for OZEMPIC, the terms “cardiologist” and “endocrin” did not appear. [5][6]
Prescribing Authority Under State Scope of Practice
Whether a gastroenterologist may prescribe semaglutide is governed by state licensure and scope-of-practice rules for prescribing physicians. [7] State medical-board scope-of-practice determinations and state licensing requirements define which licensed clinicians may prescribe medications. [7]
Situations Where a “Specialty-Only” Requirement Can Still Apply
Some payer prior-authorization or coverage criteria may require “prescribed by, or in consultation with, an endocrinologist” for certain semaglutide products. [8] A payer requirement affects insurance coverage or approval. [8] A payer requirement does not change FDA prescriber labeling for the drug itself. [1][2]
Practical Determination Steps
Verify the specific semaglutide product (for example, WEGOVY vs OZEMPIC) and review the FDA prescribing information for prescriber restrictions. [1][2] Confirm the gastroenterologist’s state licensure and prescribing scope of practice with the relevant state medical board. [7] If insurance coverage is the issue, check the plan’s prior-authorization criteria for any specialty-consultation requirement. [8]
Direct Answer
Yes. A gastroenterologist may prescribe semaglutide if permitted by state scope-of-practice rules for prescribing physicians. [7] FDA labeling for semaglutide products reviewed does not restrict prescribing to cardiologists or endocrinologists. [1][2][3][4][5][6]